Industry news that matters to you.  Learn more

Biodesix’ VeriStrat Diagnostic Earns Inclusion in Oncology Guidelines

Biodesix Inc., a molecular diagnostics company dedicated to advancing precision medicine and improved patient care, recently announced that its VeriStrat® blood-based prognostic and predictive proteomics test has been approved for inclusion in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).

IntegraGen Announces Publication of Study with Biomarker Associated with Survival in Metastatic Colorectal Cancer Patients Treated with Drug Therapy

IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, recently announced the publication of a study in Clinical Cancer Research which reports on the ability of the microRNA (miRNA) miR-31-3p to predict progression-free survival in KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with anti-epidermal growth factor receptor (EGFR) antibodies.

Large International Tumor Profiling Study of Colorectal Cancer Provides Key Treatment Insights for World’s Third Most Common Cancer

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, recently presented a large international tumor profiling study of colorectal cancer at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by Caris Molecular Intelligence™ the study represents the largest, multi-national analysis in a single laboratory setting of the main molecular anomalies in colorectal cancer. Colorectal cancer (CRC) is the third most common cancer worldwide, with metastatic disease accounting for 40 to 50 percent of newly diagnosed patients.

Surveyed EU5 Medical Oncologists Prescribe Iressa or Tarceva as a First-Line Treatment to an Average of 70 Percent of Their Confirmed EGFR-Mutation Positive NSCLC Patients

Interviewed payers say biomarker-driven prescribing is a non-small-cell lung cancer  (NSCLC) market access lever, but optimal pivotal trial design is also key, according to a new report from Decision Resources.

QIAGEN announces partnership with Clovis Oncology to co-develop companion diagnostic targeting drug-resistant EGFR mutations

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced a partnership with Clovis Oncology (NASDAQ: CLVS) to co-develop and co-commercialize a companion diagnostic test to guide the use of CO-1686, a novel Clovis Oncology product candidate currently in clinical development. The Clovis drug candidate will initially target an unmet clinical need in patients with epidermal growth factor receptor (EGFR) driven non-small cell lung cancer (NSCLC) for whom current EGFR-inhibiting drugs no longer control disease.